An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 13 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 13 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.